Placenta choriodecidual membrane-derived mesenchymal stem cells(BioSpring)

N/A

Report date: 2023/06/06 20:00:40

Base Information

Drug NamePlacenta choriodecidual membrane-derived mesenchymal stem cells(BioSpring)
Drug Alias NameMatriPlax(BioSpring)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioSpring Medical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBioSpring Medical Co Ltd
Inactive CompaniesN/A
Active IndicationsRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A